A new trading day began on Monday, with Esperion Therapeutics Inc (NASDAQ: ESPR) stock price down -8.51% from the previous day of trading, before settling in for the closing price of $3.88. ESPR’s price has ranged from $0.69 to $4.18 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 40.11%. Meanwhile, its annual earnings per share averaged 57.54%. With a float of $235.40 million, this company’s outstanding shares have now reached $239.06 million.
Esperion Therapeutics Inc (ESPR) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc is 1.53%, while institutional ownership is 53.03%. The most recent insider transaction that took place on Dec 17 ’25, was worth 177,200. In this transaction President and CEO of this company sold 48,244 shares at a rate of $3.67, taking the stock ownership to the 1,470,587 shares. Before that another transaction happened on Dec 17 ’25, when Company’s Chief Financial Officer sold 7,337 for $3.67, making the entire transaction worth $26,905. This insider now owns 467,525 shares in total.
Esperion Therapeutics Inc (ESPR) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.1 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.54% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Here are Esperion Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit 0.29 in the next quarter and is forecasted to reach 0.07 in one year’s time.
